Cancerous Target Equipment
-
based in USA
Circumventing drug toxicity and drug resistance is key to effective anticancer therapy. Da Zen’s products and technologies deliver targeted anticancer drugs, such as simvastatin and cisplatin conjugated to a cancer targeting dye-carrier, exclusively to cancer cells, with the drugs confined to the cancer ...
-
Manufactured by IMV Inc.based in CANADA
Maveropepimut-S (DPX-Survivac) combines the advantages of the DPX platform and the cancer antigen survivin, is the lead candidate of IMV’s new class of immunotherapies that generates cancer-targeted T cells in ...
-
Manufactured by TVAX Biomedical, Inc.based in USA
TVAX®’s lead candidate (TVI-Brain-1) is being evaluated for the treatment of brain cancer and targets glioblastomas. The drug candidate has received Fast Track Designation by the US Food and Drug Administration (FDA) to test TVI-Brain-1 in a Phase 2b clinical study for glioblastoma multiforme (GBM). The Fast Track ...
-
Manufactured by Reglagene Holding, Inc.based in USA
RGN3118 is a potent, orally administered, blood-brain barrier penetrant therapy that has been optimized for the treatment of high-grade gliomas, such as glioblastoma as well as brain metastases from breast, lung, and melanoma cancers. ...
-
Manufactured by Lightpoint Medical, Ltdbased in UNITED KINGDOM
SENSEI is an advanced guidance system for minimally-invasive and robot-assisted surgical procedures, offering unprecedented intracavity maneuverability and anatomic ...
-
Manufactured by Lightpoint Medical, Ltdbased in UNITED KINGDOM
SENSEI is an advanced guidance system for minimally-invasive cancer surgery, offering unprecedented intracavity maneuverability and anatomic ...
-
Manufactured by Lightpoint Medical, Ltdbased in UNITED KINGDOM
An advanced guidance system designed for intracavity radio-guided surgery. The miniaturized SENSEI® probe enables unprecendented dexterity and anatomic reach, expanding the field of view and enabling the quick localization of radioactive hotspots. Suitable for minimally-invasive and robot-assisted surgical ...
-
Manufactured by TVAX Biomedical, Inc.based in USA
TVAX®’s second candidate (TVI-Kidney-1) is being evaluated for the treatment of kidney cancer and targets stage 4 renal cell ...
-
Manufactured by Datar Cancer Geneticsbased in UNITED KINGDOM
CellDx is an intensive and in-depth tumor molecular profiling. It analyses millions of data points at the molecular level to reveal threats and vulnerabilities which enable optimal identification of targets for precision treatment ...
-
Manufactured by EirGenix, Incbased in TAIWAN
Product: New Formulation. Indication: Cancer. Target: HER2. Status: ...
-
Manufactured by EirGenix, Incbased in TAIWAN
Product: EG12014/EGI014 Trastuzumab Biosimilar. Indication: Cancer. Target: HER2. Status: ...
-
Manufactured by EirGenix, Incbased in TAIWAN
Product: EG1206A Pertuzumab Biosimilar. Indication: Cancer. Target: HER2. Status: Phase ...
-
Manufactured by EirGenix, Incbased in TAIWAN
Product: EG12021 Bevacizumab Biosimilar. Indication: Cancer. Target: VEGF. Status: ...
-
Manufactured by EirGenix, Incbased in TAIWAN
Product: TSY0110 (EG12043) Antibody-Drug Conjugate. Indication: Cancer. Target: HER2. Status: ...
-
by Astraveusbased in FRANCE
Macrophages are versatile cells. They exhibit abilities to survive solid tumor microenvironment, to trigger inflammation and to absorb and digest debris or infected cells. CAR-Macrophages (CAR-M) are artificially directed against a cancerous target by a chimeric antigen receptor. CAR-M are still in their clinical infancy, however ...
-
Manufactured by ALL Chemistry Inc.based in USA
TJ191 is a selective anti-cancer agent, targeting low TĪ²RIII-expressing malignant T-cell leukemia/lymphoma ...
-
Manufactured by Cancer Targeted Technologybased in USA
CTT’s lead therapeutic product, CTT1403, is a PSMA-targeted 177Lu-labeled agent for prostate cancer that can has superior binding characteristics, long circulation half-life, enhanced tumor uptake and unparalleled anti-tumor efficacy. CTT1403 will specifically deliver the radionuclide, 177Lu, minimizing toxic side effects and ...
-
Manufactured by Cancer Targeted Technologybased in USA
CTT1057 is an innovative 18F-labeled PET agent for prostate cancer that can be imaged within 2 hours of administration. CTT1057 will specifically and sensitively detect cancer that has escaped from the prostate as well as distant metastatic disease including bone metastases with greater precision and resolution than current standard of ...
-
by Genmab A/Sbased in DENMARK
Amivantamab is a fully human bispecific antibody that targets EGFR and Met, two validated cancer targets. In July 2012, Genmab entered into a collaboration with Janssen Biotech, Inc. to create and develop bispecific antibodies using Genmab’s DuoBody® technology platform. The two antibody libraries used to produce amivantamab were ...
-
Manufactured by Scancellbased in UNITED KINGDOM
SCIB2 is the second cancer vaccine based on the ImmunoBody® technology and encodes a modified antibody engineered to express the cancer antigen NY-ESO-1. This is a well-characterised and validated cancer target, being overexpressed in several tumour types including synovial sarcomas, oesophageal, liver, gastric, prostate and ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you